References
- E. Germovsek, C. I. S. Barker, M. Sharland and J. F. Standing, Pharmacokinetic-pharmacodynamic modeling in pediatric drug development, and the importance of standardized scaling of clearance, Clin. Pharmacokinet. 58(1) (2019) 39–52; https://doi.org/10.1007/s40262-018-0659-0
- H. Kimko and J. Pinheiro, Model-based clinical drug development in the past, present and future: a commentary, Br. J. Clin. Pharmacol. 79(1) (2015) 108–116; https://doi.org/10.1111/bcp.12341
- K. J. Downes, A. Hahn, J. Wiles, J. D. Courter and A. A. Vinks, Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics, Int. J. Antimicrob. agents 43(3) (2014) 223–230; https://doi.org/10.1016/j.ijantimicag.2013.11.006
- R. F. W. De Cock, C. Piana, E. H. J. Krekels, M. Danhof, K. Allegaert and C. A. J. Knibbe, The role of population PK-PD modelling in paediatric clinical research, Eur. J. Clin. Pharmacol. 67 (2011) 5–16; https://doi.org/10.1007/s00228-009-0782-9
- UpToDate: Gentamicin (systemic): Pediatric drug information, 2022; last access date February 20, 2023.
- M. H. Abdul-Aziz, J.-W. C. Alffenaar, M. Bassetti, H. Bracht, G. Dimopoulos, D. Marriott, M. N. Neely, J.-A. Paiva, F. Pea and F. Sjovall, Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#, Intensive Care Med. 46 (2020) 1127–1153; https://doi.org/10.1007/s00134-020-06050-1
- C. J. Hodiamont, A. K. van den Broek, S. L. de Vroom, J. M. Prins, R. A. Mathôt and R. M. van Hest, Clinical pharmacokinetics of gentamicin in various patient populations and consequences for optimal dosing for gram-negative infections: an updated review, Clin. Pharmacokinet. 61 (2022) 1075–1094; https://doi.org/10.1007/s40262-022-01143-0
- P. Póvoa, P. Moniz, J. G. Pereira and L. Coelho, Optimizing antimicrobial drug dosing in critically ill patients, Microorganisms 9(7) (2021) Article ID 1401 (27 pages); https://doi.org/10.3390/micro-organisms9071401
- J. M. Lanao, M. V. Calvo, J. A. Mesa, A. Martín-Suárez, M. T. Carbajosa, F. Miguelez and A. Domínguez-Gil, Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates, J. Antimicrob. Chemother. 54(1) (2004) 193–198; https://doi.org/10.1093/jac/dkh261
- A. M. Jenh, P. D. Tamma and A. M. Milstone, Extended-interval aminoglycoside dosing in pediatrics, The Pediatr. Infect. Dis. J. 30(4) (2011) 338–339; https://doi.org/10.1097/INF.0b013e31820f0f3a
- S. J. McWilliam, D. J. Antoine, R. L. Smyth and M. Pirmohamed, Aminoglycoside-induced nephrotoxicity in children, Pediatr. Nephrol. 32 (2017) 2015–2025; https://doi.org/10.1007/s00467-016-3533-z
- F. A. Diepstraten, A. E. Hoetink, M. van Grotel, A. D. R. Huitema, R. J. Stokroos, M. M. van den Heuvel-Eibrik and A. J. M. Meijer, Aminoglycoside-and glycopeptide-induced ototoxicity in children: a systematic review, JAC-Antimicrob. Resist. 3, dlab184 (2021), https://doi.org/10.1093/jacamr/dlab184
- A. Smits, P. Annaert and K. Allegaert, Drug disposition and clinical practice in neonates: cross talk between developmental physiology and pharmacology, Int. J. Pharm. 452(1–2) (2013) 8–13; https://doi.org/10.1016/j.ijpharm.2012.03.035
- H. Lu and S. Rosenbaum, Developmental pharmacokinetics in pediatric populations, J. Pediatr. Pharmacol. Ther. 19(4) (2014) 262–276; https://doi.org/10.5863/1551-6776-19.4.262
- Y. A. Bijleveld, M. E. van den Heuvel, C. J. Hodiamont, R. A. Mathôt and T. R. de Haan, Population pharmacokinetics and dosing considerations for gentamicin in newborns with suspected or proven sepsis caused by Gram-negative bacteria, Antimicrob. Agents Chemother. 61(1) (2017) e01304-16; https://doi.org/10.1128/AAC.01304-16
- S. J. F. Hartman, R. J. Brüggemann, L. Orriëns, N. Dia, M. F. Schreuder, S. N. De Wildt, Pharmacokinetics and target attainment of antibiotics in critically ill children: a systematic review of current literature, Clin. Pharmacokinet. 59 (2020) 173–205; https://doi.org/10.1007/s40262-019-00813-w
- N. Thakkar, S. Salerno, C. P. Hornik and D. Gonzalez, Clinical pharmacology studies in critically ill children, Pharm. Res. 34 (2017) 7–24; https://doi.org/10.1007/s11095-016-2033-y
- D. J. Touw, E. M. Westerman and A. J. Sprij, Therapeutic drug monitoring of aminoglycosides in neonates, Clin. Pharmacokinet. 48 (2019) 71–88; https://doi.org/10.2165/0003088-200948020-00001
- M. Crcek, J. Zdovc and M. Kerec Kos, A review of population pharmacokinetic models of gentamicin in paediatric patients, J. Clin. Pharm. Ther. 44 (55) (2019) 659–674; https://doi.org/10.1111/jcpt.12850
- L. Martin, N. Jimenez and A. M. Lynn, Developmental pharmacokinetics and pharmacodynamics of parenteral opioids and nonsteroidal anti-inflammatory drugs in neonates and infants, Colomb. J. Anestesiol. 45 (2017), 72–79; https://doi.org/10.1016/j.rcae.2016.11.011
- A. N. Mian and G. J. Schwartz, Measurement and estimation of glomerular filtration rate in children, Adv. Chronic Kidney Dis 24 (2017) 348–356; https://doi.org/10.1053/j.ackd.2017.09.011
- L. Kahl and H. K. Hughes, The Harriet Lane Handbook, 21nd ed., Elsevier, Amsterdam 2018.
- ICH E11(R1) step 5 guideline on clinical investigation of medicinal products in the pediatric population - Scientific guideline 2017; https://www.ema.europa.eu/en/ich-e11r1-step-5-guideline-clinical-investigation-medicinal-products-pediatric-population-scientific; last access date February 20, 2023.
- M.-A. Decrocq-Rudler, A. H. X. P. C. Kwong, L. Meunier, J. Fraisse, J. Ursic-Bedoya and S. Khier, Can we predict individual concentrations of tacrolimus after liver transplantation? Application and tweaking of a published population pharmacokinetic model in clinical practice, Ther. Drug Monit. 43(4) (2921) 490–498; https://doi.org/10.1097/FTD.0000000000000867
- A. Chan Kwong, A. O’Jeanson and S. Khier, Model-informed therapeutic drug monitoring of meropenem in critically ill patients: improvement of the predictive ability of literature models with the PRIOR approach, Eur. J. Drug Metab. Pharmacokinet. 46 (2021) 415–426; https://doi.org/10.1007/s13318-021-00681-5
- A. Gomes, L. van der Wijk, J. H. Proost, B. Sinha and D. J. Touw, Pharmacokinetic modeling of gentamicin in treatment of infective endocarditis: Model development and validation of existing models, PloS One 12(5) (2017) e0177324 (13 pages); https://doi.org/10.1371/journal.pone.0177324
- J. H. Hughes, D. M. H. Tong, S. S. Lucas, J. D. Faldasz, S. Goswami and R. J. Keizer, Continuous learning in model-informed precision dosing: a case study in pediatric dosing of vancomycin, Clin. Pharmacol. Ther. 109(1) (2021) 233–242; https://doi.org/10.1002/cpt.2088
- W. Zhao, F. Kaguelidou, V. Biran, D. Zhang, K. Allegaert, E. V. Capparelli, N. Holford, T. Kimura, Y. L. Lo, J. E. Peris, External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings, Br. J. Clin. Pharmacol. 75(4) (2013) 1068–1080; https://doi.org/10.1111/j.1365-2125.2012.04406.x
- C. Schräpel, L. Kovar, D. Selzer, U. Hofmann, F. Tran, W. Reinisch, M. Schwab and T. Lehr, External model performance evaluation of twelve infliximab population pharmacokinetic models in patients with inflammatory bowel disease, Pharmaceutics 13(9) (2021) Article ID 1368 (21 pages); https://doi.org/10.3390/pharmaceutics13091368
- K. R. Knøsgaard, D. J. R. Foster, M. Kreilgaard, E. Sverrisdóttir, R. N. Upton and J. N. van den Anker, Pharmacokinetic models of morphine and its metabolites in neonates: Systematic comparisons of models from the literature, and development of a new meta-model, Eur. J. Pharm. Sci. 92 (2016) 117–130; https://doi.org/10.1016/j.ejps.2016.06.026
- D. M. Tong, J. H. Hughes and R. J. Keizer, Evaluating and improving neonatal gentamicin pharmacokinetic models using aggregated routine clinical care data, Pharmaceutics 14(10) (2022) Article ID 2089 (14 pages); https://doi.org/10.3390/pharmaceutics14102089
- A. H.-X. Chan Kwong, E. A. Calvier, D. Fabre, F. Gattacceca and S. Khier, Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine, J. Pharmacokinet. Pharmacodyn. 47 (2020) 431–446; https://doi.org/10.1007/s10928-020-09695-z
- A. Duong, C. Simard, D. Williamson and A. Marsot, Model re-estimation: An alternative for poor predictive performance during external evaluations? Example of gentamicin in critically ill patients, Pharmaceutics 14(7) (2022) 1426; https://doi.org/10.3390/pharmaceutics14071426
- C. C. Llanos-Paez, C. E. Staatz, R. Lawson and S. Hennig, A population pharmacokinetic model of gentamicin in pediatric oncology patients to facilitate personalized dosing, Antimicrob. Agents Chemother. 61(8) (2017) e00205-17; https://doi.org/10.1128/AAC.00205-17
- S. A. Lopez, H. Mulla, A. Durward and S. M. Tibby, Extended-interval gentamicin: population pharmacokinetics in pediatric critical illness, Pediatr. Crit. Care Med. 11(2) (2010) 267–274; https://doi.org/10.1097/PCC.0b013e3181b80693
- R. F. W. De Cock, K. Allegaert, J. M. Brussee, C. M. T. Sherwin, H. Mulla, M. de Hoog, J. N. van den Anker, M. Danhof and C. A. J. Knibbe, Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration, Pharm. Res. 31 (2014) 2643–2654;, https://doi.org/10.1007/s11095-014-1361-z
- A. Alsultan, M. Abouelkheir, Y. Elsharawy, A. Alkoraishi, R. Osman, M. N. Neely, W. Mansy and S. Algahtani, Optimizing gentamicin dosing in pediatrics using monte carlo simulations, Pediatr. Infect. Dis. J. 38(4) (2019) 390–395; https://doi.org/10.1097/INF.0000000000002120
- C. C. Llanos-Paez, C. E. Staatz, R. Lawson and S. Hennig, Differences in the pharmacokinetics of gentamicin between oncology and nononcology pediatric patients, Antimicrob. Agents Chemother. 64(2) (2020) e01730-19; https://doi.org/10.1128/AAC.01730-19
- H. Wang, C. Sherwin, J. V. S. Gobburu and V. Ivaturi, Population pharmacokinetic modeling of gentamicin in pediatrics, J. Clin. Pharmacol. 59(12) (2019) 1584–1596; https://doi.org/10.1002/jcph.1479
- R. H. Ghoneim, A. K. Thabit, M. O. Lashkar and A. S. Ali, Optimizing gentamicin dosing in different pediatric age groups using population pharmacokinetics and Monte Carlo simulation, Ital. J. Pediatr. 47 (2021) Article ID 167 (8 pages); https://doi.org/10.1186/s13052-021-01114-4
- H. S. Al-Sallami, A. Goulding, A. Grant, R. Taylor, N. Holford and S. B. Duffull, Prediction of fat-free mass in children, Clin. Pharmacokinet. 54 (2015) 1169–1178; https://doi.org/10.1007/s40262-015-0277-z
- J. Valles, J. Rello, A. Ochagavía, J. Garnacho and M. A. Alcalá, Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival, Chest 123(5) (2003) 1615–1624; https://doi.org/10.1378/chest.123.5.1615
- A. Coste, G. Deslandes, L. Jalin, S. Corvec, J. Caillon, D. Boutoille, M. Grégoire and C. Bretonnière, PK/PD targets of amikacin and gentamicin in ICU patients, Méd. Mal. Infect. 50(8) (2020) 709–714; https://doi.org/10.1016/j.medmal.2019.12.003
- A. A. Marsot, A. Boulamery, B. Bruguerolle and N. Simon, Population pharmacokinetic analysis during the first 2 years of life: an overview, Clin. Pharmacokinet. 51 (2012) 787–798; https://doi.org/10.1007/s40262-012-0015-8
- F. Ceriotti, J. C. Boyd, G. Klein, J. Henny, J. Queralto, V. Kairisto and M. Panteghini, Reference intervals for serum creatinine concentrations: assessment of available data for global application, Clin. Chem. 54(3) (2008) 559–566; https://doi.org/10.1373/clinchem.2007.099648